BioCentury
ARTICLE | Emerging Company Profile

Orphazyme: One for all

Denmark's Orphazyme developing Hsp70 for lysosomal storage disorders

November 7, 2011 8:00 AM UTC

Drug development for lysosomal storage disorders has largely centered on enzyme replacement therapies, which yield one drug per disease. Orphazyme ApS believes its recombinant heat shock protein 70 (Hsp70) and small molecules that induce heat shock protein expression will be able to treat a variety of lysosomal storage disorders.

The company was founded based on work by co-founder and CSO Thomas Kirkegaard Jensen while he was a postdoctoral fellow at the Danish Cancer Society's Institute of Cancer Biology...